Clinical Trials Logo

Clinical Trial Summary

This study specifically seeks to provide data on the safety, tolerability and pilot efficacy of short course, high dose primaquine treatment in Papua New Guinean children aged 5-10 years, in a cross-sectional study design. Community screened asymptomatic cases and/or cases of clinically diagnosed malaria admitted to the out-patient units of the health center, will be screened for Glucose-6-phosphate dehydrogenase deficiency (G6PD) and malaria illness by rapid diagnostic test and P. vivax infection confirmed by light microscopy. Following treatment with artemether-lumefantrine (Coartem), G6PD normal children will be enrolled into the study and followed for 2 months. Primaquine treatment will be allocated to study participants in a step-wise design; firstly receiving the current 14 day treatment regimen of 0.5 mg/kg total dose (n=40); secondly, a 7 day treatment regimen receiving a total dose of 1.0 mg/kg/day; then thirdly, receive 1.0 mg/kg twice daily dose (bd) for a total of 3.5 days, should the 7 day treatment prove to be safe and well tolerated. In addition to this dose-escalation study, the pharmacokinetic profiles of single doses of 0.5 mg/kg and 1.0 mg/kg will be determined using an intensive sampling protocol, in children aged 5-10 years. The pharmacokinetic profiles obtained by this sub-study will be essential for modeling the population pharmacokinetic data obtained from the dose-escalation study. As there is currently no data on the safety, tolerability and efficacy of primaquine in children, the present study will validate previous observation and contribute to the knowledge of primaquine as a treatment for liver stages of Plasmodium vivax infection.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02364583
Study type Interventional
Source Papua New Guinea Institute of Medical Research
Contact Inoni Betuela, MD PhD
Email inoni.betuela@pngimr.org.pg
Status Recruiting
Phase Phase 4
Start date June 2010
Completion date December 2016

See also
  Status Clinical Trial Phase
Terminated NCT01290601 - Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults Phase 2
Recruiting NCT02610686 - Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam Phase 4
Completed NCT05527119 - Phenotyping and Genotyping of Duffy Antigen
Terminated NCT04445103 - The Malaria Heart Disease Study
Completed NCT02802813 - P.Vivax Treatment Trial Phase 1/Phase 2
Completed NCT01157897 - Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults Phase 1/Phase 2
Active, not recruiting NCT06392152 - Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar N/A
Recruiting NCT04411836 - Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine Phase 3
Completed NCT01816113 - Phase Ia Study of ChAd63/MVA PvDBP Phase 1